Carlsmed, Inc.’s Lock-Up Period Set To End on January 19th (NASDAQ:CARL)

Carlsmed’s (NASDAQ:CARL) lock-up period will end on Monday, January 19th. Carlsmed had issued 6,700,000 shares in its initial public offering on July 23rd. The total size of the offering was $100,500,000 based on an initial share price of $15.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Analyst Upgrades and Downgrades

CARL has been the topic of several analyst reports. The Goldman Sachs Group reiterated a “buy” rating and set a $20.00 price target on shares of Carlsmed in a research note on Friday. Wall Street Zen upgraded Carlsmed from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. BTIG Research reissued a “buy” rating and set a $24.00 price target on shares of Carlsmed in a report on Monday, December 15th. Weiss Ratings reaffirmed a “sell (e-)” rating on shares of Carlsmed in a research note on Monday, December 22nd. Finally, Truist Financial reaffirmed a “buy” rating and set a $20.00 price objective (up from $18.00) on shares of Carlsmed in a research report on Friday, November 7th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Carlsmed has an average rating of “Moderate Buy” and an average target price of $21.33.

Carlsmed Stock Down 1.2%

Shares of Carlsmed stock opened at $14.27 on Wednesday. The stock has a market capitalization of $379.48 million and a P/E ratio of -4.27. The company has a quick ratio of 11.91, a current ratio of 12.03 and a debt-to-equity ratio of 0.14. The firm has a 50-day simple moving average of $13.26. Carlsmed has a 52 week low of $11.45 and a 52 week high of $17.19.

Carlsmed (NASDAQ:CARL) last issued its earnings results on Thursday, November 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.05.

Hedge Funds Weigh In On Carlsmed

Several institutional investors have recently bought and sold shares of the stock. BNP Paribas Financial Markets bought a new position in Carlsmed during the third quarter valued at approximately $33,000. JPMorgan Chase & Co. purchased a new stake in Carlsmed during the third quarter valued at approximately $37,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Carlsmed in the 3rd quarter valued at approximately $42,000. Rhumbline Advisers purchased a new position in shares of Carlsmed in the 3rd quarter worth approximately $79,000. Finally, Bank of America Corp DE purchased a new position in shares of Carlsmed in the 3rd quarter worth approximately $202,000.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).